Other languages LENSAR, Inc.

Equities

LNSR

US52634L1089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-03 pm EDT			5-day change	1st Jan Change
4.64 ^USD	-1.28%		+10.74%	+32.19%

May. 09	LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Transcript : LENSAR, Inc., Q1 2024 Earnings Call, May 09, 2024

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
LENSAR, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04
Top Premarket Gainers	Nov. 28
LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
LENSAR, Inc. Announces Retirement of John P. McLaughlin from the Board, Effective October 31, 2023	23-10-13
LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Lensar, Inc. Reports Adoption of Ally System in Multi-Center Ophthalmology Groups	23-07-24
LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
LENSAR, Inc. Provides Revenue Guidance for the Fiscal 2023	23-03-16
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-16
LENSAR, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16
LENSAR, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09
Lensar, Inc. Announces Application for Certification of the Ally Adaptive Cataract Treatment System in the Eu	22-09-08
LENSAR, Inc. Announces First Patients Treated with LENSAR's(R) ALLY(TM) Adaptive Cataract Treatment System	22-08-16
LENSAR, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08
Earnings Flash (LNSR) LENSAR Reports Q2 Revenue $8M	22-08-08
LENSAR Secures FDA Clearance of ALLY Adaptive Cataract Treatment System	22-06-13
LENSAR, Inc. Receives U.S. FDA Clearance of Ally(Tm) Adaptive Cataract Treatment System	22-06-13
LENSAR, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages LENSAR, Inc.

Equities

LNSR

US52634L1089

Other languages

Filters